July 09, 2026

Prolonged Sleep Restriction May Increase Body Weight

In a pooled analysis of two randomized crossover trials, reducing nightly sleep by about 1.5 hours for 6 weeks was associated with modest increases in body weight and waist circumference without measurable changes in body composition.

Conexiant

July 06, 2026

Why Is Vaginal Estrogen Still Underused?

A large Epic Cosmos analysis linked vaginal estrogen prescribing with lower rates of sepsis, hospital admission, and death following recurrent urinary tract infection, but researchers cautioned that prescribing may also mark broader differences in care.

Conexiant

June 30, 2026

How Does Social Media Influence Health Decisions?

National survey findings suggest many US adults report making health decisions based on social media despite widespread concerns about the accuracy of health information shared to the platforms.

Conexiant

June 25, 2026

Medical Oddities: Could GLP-1s Curb Violence?

Five studies, one question: are we overlooking hidden drivers of health?

Conexiant

June 16, 2026

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.

Conexiant

June 11, 2026

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Conexiant

May 28, 2026

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

Conexiant

May 27, 2026

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.

Conexiant

May 27, 2026

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

Conexiant

May 21, 2026

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

Conexiant